2024-514089-37-00RecruitingPhase 2
Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Apr 2026
Brief summary (registry, in English)
• To identify number of lymph nodes removed in patients having a nephroureterectomy for renal cancer where surgery includes the use of ICG/NIRF for lymph node harvest and compare this data to those who have had the same surgery but without the use of ICG/NIRF • To identify number of lymph nodes removed during retroperitoneal lymph node dissection (RPLND) for paratesticular rhabdomyosarcoma in patients having ICG guided nodal harvest
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 13 Jan 2026
- Start date
- 16 Jun 2026
- Lead sponsor
- The University Of Birmingham
- Diseases
- Childhood cancers, Neuroblastoma, Sarcoma
- EU CT number
- 2024-514089-37-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people having cancer surgery, including surgery for pulmonary metastasis, a renal tumour or para-testicular rhabdomyosarcoma. Surgery uses ICG and near infrared fluorescence.
- Sex
- All sexes can join.
- Disease stage
- Cohort 2: any renal tumour needing surgery and sampling of lymph nodes behind the abdomen (retroperitoneal). Cohort 3: para-testicular rhabdomyosarcoma, confirmed or presumed, with planned sampling of lymph nodes on the same side (RPLND). Surgery is open, or keyhole (thoracoscopic, transperitoneal or retroperitoneoscopic).
- Earlier treatment
- Patients cannot join if they have already been randomised in Cohort 1 or in the same cohort. Patients cannot join if they are due to receive radioactive iodine as part of treatment.
Main reasons for not taking part
- Allergy to ICG, iodine or iodides
- Known hyperthyroidism
- eGFR <15 ml/min/1.73 m2
- Female patients who are breastfeeding
- Neonates needing exchange transfusion
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cohort 2: Have entered a previous randomisation within Cohort 1
- Cohort 3: Have entered a previous randomisation within Cohort 1
- Have entered a previous randomisation within the same cohort
Other illness
- Allergic to ICG
- Allergic to iodine or iodides
Lab values
- eGFR <15 ml/min/1.73 m2
Other
- Cohort 2: Renal tumour requiring extensive retroperitoneal or hilar dissection to access normal renal parenchyma for the ICG injection as this could damage the lymphatic vessels
- Due to receive radioactive iodine as part of treatment
- Known Hyperthyroidism
- Female patients who are breastfeeding
- Neonates requiring exchange transfusion
- Cohort 2: Kidney wholly replaced by tumour on pre-operative imaging
Who the study is looking for
- Undergoing surgery via open laparotomy and/or thoracotomy, minimally invasive thoracoscopic, transperitoneal or retroperitoneoscopic surgery
- Documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry
- Sexually active male and female patients of childbearing potential must agree to use adequate and highly effective contraception while on study up until discharge
- Written informed consent from the patient, parent or guardian
- Cohort 2: Any renal tumour requiring surgical resection and retroperitoneal lymph node sampling
- Cohort 3: Histologically confirmed or presumed diagnosis of para-testicular RMS (ptRMS) with the intention to sample nodes from the ipsilateral retroperitoneum according to template dissection. Otherwise known as Retroperitoneal Lymph Node Dissection (RPLND)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prinses Maxima Centrum voor Kinderoncologie B.V. | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.